FLUENCE-TECHNOLOGIES
5.7.2022 14:47:05 CEST | Business Wire | Press release
Fluence Technologies , the only provider of purpose-built financial consolidation, close and reporting software for high-growth businesses, today announced the acquisition of Sturnis365, the leading provider of intelligent, collaborative disclosure management and narrative reporting solutions.
Sturnis365 serves dozens of public, private and pre-IPO customers across Europe including AB InBev, Enel Group, Rothschild & Co., Bouygues Group, Ferragamo and KBC Bank. Like Fluence, Sturnis365 offers a familiar Microsoft Office interface and domain-specific workflow to automate collaborative report production, combining companywide data and narrative text for:
- Immediate adoption among finance and business professionals compared to reporting available in their ERP system
- Game-changing efficiency gains in report production compared to standalone Excel spreadsheets, Word and PowerPoint documents
- Trusted, accurate internal and external reporting for any stakeholder, auditor or regulator
“Sturnis365 is a natural extension of our consolidation, close and reporting solution so CFOs can stay ahead of evolving reporting demands on the office of finance,” said Michael Morrison, CEO of Fluence Technologies. “Further, Sturnis365 strengthens our position in Europe, where more than 70% of their customers and partners are based. We also gain seasoned employees with strong ‘DNA’ in collaborative disclosure management.”
“We are excited about the value Fluence and Sturnis365 presents to our customers and partners,” said Didier Katz, co-founder and director at Sturnis365. “Companies across the globe are looking for a solution that combines financial consolidation, close and disclosure management in a single offering. Now, Fluence is the only player on the market that can meet this need."
Katz and fellow Sturnis365 co-founders Marco Mattei and Piero Ferreri are joining Fluence’s leadership team as part of the acquisition, along with their respective teams in product development, services, sales and marketing.
Fluence and Sturnis365 have already secured joint customers including cryptocurrency trading platform provider WonderFi.
“When we learned about Sturnis365, we were considering a legacy disclosure management solution that would have cost a significant amount and taken months to implement,” said John Rim, CFO at WonderFi. “Between its out-of-the-box functionality, Office integration and the fact that our finance team can manage the entire reporting process, we quickly realized how much more we’d benefit from Sturnis365.”
“Today’s CFOs don’t just need modern consolidation software, but end-to-end group accounting solutions spanning from account reconciliation to disclosure management.” said Carsten Bange, founder and CEO of BARC. “With its acquisition of Sturnis365, Fluence has broadened its offering to meet the changing needs of the constantly evolving finance function.”
"Acquiring Sturnis365 continues building on the vision of a complete financial corporate performance management suite that Michael Morrison and our team had when we originally invested in Fluence,” said Stephen Davis, managing partner at Banneker Partners, Fluence’s principal investor. “We look forward to Fluence continuing to deliver exceptional value to its customers."
The announcement comes just over six months after Fluence acquired self-serve, Excel-centric reporting software vendor XLCubed, and three months after unveiling its purpose-built account reconciliation and transaction matching solution. As a result, Fluence now has the market’s only end-to-end consolidation, close and reporting solution, and over 900 customers worldwide.
For more information on Fluence’s disclosure management and narrative reporting solution, visit: https://www.fluencetech.com/disclosuremanagement/home
About Fluence Technologies - www.fluencetech.com
Fluence is the only pure-play financial consolidation, close and reporting software for high growth businesses. Our customers go live in weeks, close their books in days and report intelligence in real time. We deliver game-changing efficiency gains and trusted, timely numbers to over 900 customers so they get the time, control and confidence they deserve. Fluence is out-of-the-box, no-coding software with a full Excel interface and enterprise-grade capabilities for immediate adoption and quick time to value, all in a truly finance-owned solution. Welcome to Fluence...we close early.
About Sturnis365 - www.sturnis365.com
Sturnis365 provides full end-user collaborative creation, publication and disclosure of corporate information, including for annual and periodical corporate reports, sustainability and ESG reporting, compliance and risk reporting and procurement and tax disclosures. Our unique Inversed Design capability allows for automated data synchronization to reduce document setup and maintenance and optimize overall cost of ownership.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005268/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
